CompletedNCT03662763
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
Medication studyAges 6–17NetherlandsADHD
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- MaastrichtSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Maastricht University Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Netherlands
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT03662763
- Official title
Show the full official title
Phase 3,Double Blind,Placebo-controlled,Multicentre,Randomised-withdrawal,Long-term Maintenance of Efficacy&Safety Study of Extended-release Guanfacine Hydrochloride in Children/Adolescents Aged 6-17 With ADHD
Recruitment & locations
CompletedMaastricht
Questions about this study
Who is behind this study?
The study sponsor is Maastricht University Medical Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Extended-release Guanfacine Hydrochloride (SPD503) and Placebo oral capsule.
Who was this study for?
Listed age limits: 6 years to 17 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...